骨显像全因转诊中心脏淀粉样变性的患病率与结局
研究纳入2010至2020年连续接受99mTc-DPD骨显像的11,527例受试者,99mTc-DPD阳性患病率为3.3%,其中心脏转诊者阳性率(18.2%)高于非心脏转诊者(1.7%)。中位随访6年,阳性99mTc-DPD独立预测全因死亡、心血管死亡和心衰住院,不良结局主要由确诊心脏淀粉样变性驱动。
要点
- 连续骨显像转诊中99mTc-DPD阳性患病率为3.3%,其中心脏转诊者(18.2%)明显高于非心脏转诊者(1.7%)。
- 确诊心脏淀粉样变性(2级或3级)与全因死亡(AHR 1.46)、心血管死亡(AHR 2.34)和心衰住院(AHR 2.25)独立相关。
- 非肿瘤患者中1级摄取者结局亦差于0级(心衰住院/死亡AHR 1.45),可能反映早期浸润的预后影响。
核心结论
- 在连续99mTc-DPD骨显像转诊者中,阳性摄取见于相当数量受试者,并与不良结局相关。
研究设计与样本
- 纳入2010至2020年间连续接受99mTc-DPD骨显像的全因转诊受试者,共分析11,527例受试者的17,387次扫描,年龄61±16岁,女性63.0%,肿瘤患者73.6%。
- Perugini 1级定义为低级别摄取,2级或3级定义为确诊心脏淀粉样变性,终点为全因死亡、心血管死亡和心衰住院。
主要发现
- 99mTc-DPD阳性患病率为3.3%(376/11,527;1级1.8%,2级或3级1.5%),心脏转诊者阳性率为18.2%,非心脏转诊者为1.7%。
- 多次扫描者中观察到从1级进展为2级或3级;活检证实的CA患者中,1级者AL-CA比例显著高于2级或3级者(73.3% vs. 15.4%)。
- 中位随访6年,临床事件率为全因死亡29.4%、心血管死亡2.6%、心衰住院1.5%,均被阳性99mTc-DPD独立预测。
- 与0级相比,确诊CA(2级或3级)与全因死亡(AHR 1.46,95%CI 1.12-1.90)、心血管死亡(AHR 2.34,95%CI 1.49-3.68)和心衰住院(AHR 2.25,95%CI 1.51-3.37)相关。
- 非肿瘤患者中,1级者心衰住院/死亡风险亦高于0级(AHR 1.45,95%CI 1.01-2.09),推测与更长观察时间和早期浸润的预后影响有关。
关键数值与推荐
- Perugini 1级为低级别摄取,2级或3级为确诊心脏淀粉样变性。
- 99mTc-DPD阳性定义为存在摄取(含1级至3级),患病率3.3%(376/11,527)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of cardiac amyloidosis (CA) in the general population and associated prognostic implications remain poorly understood. We aimed to identify CA prevalence and outcomes in bone scintigraphy referrals. Methods: Consecutive all-comers undergoing 99mTc-3,3-diphosphono-1,2-propanodicarboxylic-acid (99mTc-DPD) bone scintigraphy between 2010 and 2020 were included. Perugini grade 1 was defined as low-grade uptake and grade 2 or 3 as confirmed CA. All-cause mortality, cardiovascular death, and heart failure hospitalization (HHF) served as endpoints. Results: In total, 17,387 scans from 11,527 subjects (age, 61 ± 16 y; 63.0% women, 73.6% cancer) were analyzed. Prevalence of 99mTc-DPD positivity was 3.3% (n = 376/11,527; grade 1: 1.8%, grade 2 or 3: 1.5%), and was higher among cardiac than noncardiac referrals (18.2% vs. 1.7%). In individuals with more than 1 scan, progression from grade 1 to grade 2 or 3 was observed. Among patients with biopsy-proven CA, the portion of light-chain (AL)-CA was significantly higher in grade 1 than grade 2 or 3 (73.3% vs. 15.4%). After a median of 6 y, clinical event rates were: 29.4% mortality, 2.6% cardiovascular death, and 1.5% HHF, all independently predicted by positive 99mTc-DPD. Overall, adverse outcomes were driven by confirmed CA (vs. grade 0, mortality: adjusted hazard ratio [AHR] 1.46 [95% CI 1.12-1.90]; cardiovascular death: AHR 2.34 [95% CI 1.49-3.68]; HHF: AHR 2.25 [95% CI 1.51-3.37]). One-year mortality was substantially higher in cancer than noncancer patients. Among noncancer patients, also grade 1 had worse outcomes than grade 0 (HHF/death: AHR 1.45 [95% CI 1.01-2.09]), presumably because of longer observation and higher prognostic impact of early infiltration. Conclusion: Positive 99mTc-DPD was identified in a substantial number of consecutive 99mTc-DPD referrals and associated with adverse outcomes.
引用
- Nitsche C, Mascherbauer K, Calabretta R, et al. Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy. J Nucl Med. 2022. PMID: 35710734. doi:10.2967/jnumed.122.264041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。